FATE THERAPEUTICS INC Annual Operating Income (Loss) in USD from 2011 to 2023

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Fate Therapeutics Inc quarterly/annual Operating Income (Loss) history and growth rate from 2011 to 2023.
Fate Therapeutics Inc Operating Income (Loss) for the quarter ending June 30, 2024 was -$45.1M, a 27.9% increase year-over-year.
Fate Therapeutics Inc Operating Income (Loss) for the twelve months ending June 30, 2024 was -$196M, a 19.2% increase year-over-year.
Fate Therapeutics Inc annual Operating Income (Loss) for 2023 was -$191M, a 38.2% increase from 2022.
Fate Therapeutics Inc annual Operating Income (Loss) for 2022 was -$308M, a 42.1% decline from 2021.
Fate Therapeutics Inc annual Operating Income (Loss) for 2021 was -$217M, a 69.4% decline from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Annual (USD)

Operating Income (Loss), YoY Annual Growth (%)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
2023	-$191M	+$118M	+38.2%	Jan 1, 2023	Dec 31, 2023	10-K	2024-02-26
2022	-$308M	-$91.4M	-42.1%	Jan 1, 2022	Dec 31, 2022	10-K	2024-02-26
2021	-$217M	-$88.9M	-69.4%	Jan 1, 2021	Dec 31, 2021	10-K	2023-02-28
2020	-$128M	-$27.4M	-27.2%	Jan 1, 2020	Dec 31, 2020	10-K	2023-02-28
2019	-$101M	-$33.6M	-50.1%	Jan 1, 2019	Dec 31, 2019	10-K	2022-02-28
2018	-$67.1M	-$25M	-59.3%	Jan 1, 2018	Dec 31, 2018	10-K	2021-02-24
2017	-$42.1M	-$10.2M	-31.8%	Jan 1, 2017	Dec 31, 2017	10-K	2020-03-02
2016	-$32M	-$4.18M	-15%	Jan 1, 2016	Dec 31, 2016	10-K	2019-03-05
2015	-$27.8M	-$2.88M	-11.6%	Jan 1, 2015	Dec 31, 2015	10-K	2018-03-05
2014	-$24.9M	-$7.23M	-40.9%	Jan 1, 2014	Dec 31, 2014	10-K	2017-03-16
2013	-$17.7M	-$4.12M	-30.4%	Jan 1, 2013	Dec 31, 2013	10-K	2016-03-03
2012	-$13.6M	-$264K	-1.99%	Jan 1, 2012	Dec 31, 2012	10-K	2015-03-12
2011	-$13.3M			Jan 1, 2011	Dec 31, 2011	10-K	2014-03-17

* An asterisk sign (*) next to the value indicates that the value is likely invalid.